Adiponectin is associated with low bone mineral density in elderly men

Lourdes Basurto 1, Rosa Galván 1, Nydia Cordova 1, Renata Saucedo 1, Columba Vargas 2, Sandra Campos 1, Elizabeth Halley 2, Francisco Avelar 2 and Arturo Zárate 1

1Endocrine Research Unit and 2Department of Radiology, National Medical Center, Instituto Mexicano del Seguro Social, Cuauhtémoc 06720 Mexico
(Correspondence should be addressed to L Basurto; Email: lbasurtost@yahoo.com)

Abstract

Objective: Recent evidence suggests that adiponectin may play a role in bone metabolism. Previous studies demonstrated that the adiponectin levels had a negative correlation with bone mineral density (BMD) in women. However, little is known about the relationship between adiponectin and BMD in men. The aim of this study was to determine the relationship between the adiponectin levels and BMD in elderly men.

Design: Cross-sectional study including 92 healthy men aged 60–80 years.

Methods: Main outcome measures were the adiponectin levels estimated by RIA and BMD at lumbar spine and femoral neck using dual energy X-ray absorptiometry.

Results: The negative correlation between adiponectin and BMD at the spine was $r = -0.209$, ($P < 0.05$) and at the femoral neck was $r = -0.237$, ($P < 0.001$). These correlations disappeared after adjustment for body mass index (BMI). When stratified by BMI, the relationship between BMD and adiponectin remained significant in the subgroup of participants with BMI $> 27$ kg/m$^2$, but disappeared in men with BMI $\leq 27$ kg/m$^2$. In multiple regression analysis, adiponectin was a significant determinant of BMD at the spine, not at the femoral neck, in those with BMI $> 27$.

Conclusion: BMD is negatively associated with the adiponectin levels in men older than 60 years and this relationship is greater in those men with BMI $> 27$, which suggests a plausible connection between bone and fat tissue.

European Journal of Endocrinology (2009) 160 289–293
ISSN 0804-4643
DOI: 10.1530/EJE-08-0569
Online version via www.eje-online.org

Introduction

There are many reports indicating that osteoporosis and particularly hip fractures are less common in obese individuals (1, 2). Body weight has generally been considered as a predictor of bone mineral density (BMD) for both males and females (3, 4). Although mechanical load forces may contribute to this relationship, other factors such as sexual hormones, glucocorticoids, and insulin are also involved (5–7). It has been recently suggested that the association of BMD with body weight might also be mediated by hormonal factors secreted by adipocytes, including leptin and adiponectin (8–11).

Adiponectin is one of the most abundant circulating proteins and it is the only adipocytokine known to date, which is negatively regulated in obesity (12). In particular, adiponectin seems to act in bone metabolism, inducing osteoblast differentiation and increasing osteoclast formation, through the stimulation of the receptor activator of nuclear factor-$\kappa B$ (RANK) pathway. This pathway, in turn, plays a role in the development of osteoporosis (13–15). The clinical association between the serum adiponectin level and BMD has been studied by several groups. In a study on adolescent women, a negative correlation was found between the adiponectin levels and BMD, which was not apparent after adjustment for fat mass (16). Richards et al. (17) found a similar association in postmenopausal women, which remained significant after adjustment for body mass index (BMI). This observation was consistent in premenopausal women (9, 18). Nevertheless, little is known about the association between the adiponectin levels and BMD in men.

We tested the hypothesis that the adiponectin levels could be negatively associated with BMD. Thus, the aim of the present study was to determine the relationship between the adiponectin levels and BMD in men older than 60 years.

Subjects and methods

This was a cross-sectional and single-center study. Ninety-two healthy men over 60 years of age were included in this study, and they were recruited from March 2004 through January 2005. The subjects were recruited by asking female participants of other studies conducted by the Endocrine Research Unit whether
they knew any man who might be interested in volunteering for the study.

Participants were interviewed for medical history and underwent a complete physical examination. Subjects with a history of diabetes, renal failure, chronic infections, malignancy, metabolic bone diseases, hypertension, history of recent cardiovascular disease, gastrointestinal or liver disease, active smoking, obesity secondary to endocrine disease, hematological abnormalities, and participation in any strenuous physical exercise were excluded from the study. Moreover, the subjects who received any medications affecting bone metabolism (vitamin D, calcium, calcitonin, bisphosphonates, or glucocorticoid) or more than 30 ml of alcoholic drinks per day were also excluded.

Body weight and height of the participants were measured without shoes, with light clothing, by using a Bane scale to a precision of 0.5 kg and a Bane stadiometer to a precision of 0.5 cm. BMI was calculated as the weight (in kg) divided by the square of the height (in m²). For analysis, two categories of BMI were defined: less than 27 kg/m², and 27.1 kg/m² or more (19, 20).

The study was approved by the ethics committee of the Instituto Mexicano del Seguro Social. The volunteers were informed about the trial, and a written consent was signed by all of them.

**Hormone analysis**

Fasting blood samples were obtained from an antecubital vein between 0730 and 0830 h using vacuum tubes with EDTA anticoagulant; these samples were promptly centrifuged at 400 g for 15 min. The plasma samples were aliquotted and stored at −70 °C until they were assayed in a single run hormone assay. The adiponectin levels were measured by a specific RIA using commercial kits from Linco Research, St Charles, MO, USA. The intra- and interassay coefficients of variation (CV) were 3.9 and 8.5% respectively. Knowing that the adiponectin levels are in μg/ml concentrations, samples were diluted to 1/500 in assay buffer before estimation. The analytical sensitivity of this assay was 0.05 μg/ml, as reported previously (21).

**Bone mineral density**

BMD was measured at the lumbar spine (L1–L4 together) and the hip (femoral neck) by dual energy X-ray absorptiometry using a Lunar distrene-plasticizer-xylene densitometer scanner (GE Lunar Corporation, Madison, WI, USA). Scanning was performed according to the instructions of the manufacturer; the CV for this technique was 1.0% in the lumbar spine and 1.3% in the hip. Calibration was performed routinely every morning using the standard provided by the manufacturer. All subjects were tested on the same machine and by the same operator.

**Statistical analysis**

The Kolmogorov–Smirnov statistical test was used to test the normality of the distributions and a parametric statistical analysis was done. The data are expressed as means±s.d. Correlation analyses between the adiponectin and anthropometric data and BMD were performed with Pearson’s correlation test and partial correlation analyses were performed to adjust for age and BMI. Regression analyses models were used to test the relationship of BMD, with adiponectin, age, and BMI. Comparisons resulting in P=0.05 were considered statistically significant. All statistical analyses were performed using the computer program statistical software SPSS version 12.0.

**Results**

Characteristics of the participants with the age ranging between 60 and 80 years are shown in Table 1. Of the total of 92 participants, 50 (54.3%) had BMI ≤27 kg/m² and 42 (45.7%) had BMI >27 kg/m². The adiponectin level of participants with overweight/obesity was reduced in comparison with participants with normal body weight (8.17 ± 3.33 vs 9.7 ± 5.59 μg/ml, P<0.05).

The Pearson correlation coefficient between the adiponectin levels and age was r=−0.271 (P<0.001), and between adiponectin and BMI was r=−0.130 (P<0.05). Moreover, adiponectin was correlated with body weight (r=−0.228, P=0.02). Table 2 shows the association between adiponectin and BMD. Adiponectin values were negatively correlated with both lumbar BMD (r=−0.209, P<0.05) and femoral BMD (r=−0.237, P<0.001). Such correlations remained significant after adjustment for age, but were not present after adjustment for BMI.

Multivariate regression models were applied to explore the relationship between adiponectin and BMD. The dependent variables were BMD at lumbar spine and femoral neck. Several independent variables such as age, BMI, and adiponectin levels were included in the regression models. When femoral neck BMD was considered as the dependent variable in a multiple regression analysis, BMI, but not the adiponectin, was

**Table 1** General characteristics of participants.

<table>
<thead>
<tr>
<th></th>
<th>n=92</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>64.3±7.7</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.6±3.4</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>74.0±8.4</td>
</tr>
<tr>
<td>Body height (m)</td>
<td>1.64±0.07</td>
</tr>
<tr>
<td>Adiponectin (μg/ml)</td>
<td>9.28±4.86</td>
</tr>
<tr>
<td>Lumbar density (g/cm²)</td>
<td>1.11±0.173</td>
</tr>
<tr>
<td>Femoral density (g/cm²)</td>
<td>0.931±0.176</td>
</tr>
</tbody>
</table>

Data are expressed as the mean (±s.d.)
the independent predictor of BMD. No significant relationships were observed with spine BMD (Table 3). When the analysis was done by considering the BMI, the subgroup of participants with BMI $\geq 27.1$ showed that adiponectin had a negative correlation with lumbar spine BMD ($r = -0.456$, $P = 0.002$) and femoral BMD ($r = -0.162$, $P < 0.05$). The above correlations remained significant after the adjustment for BMI. In this subgroup of men, multiple linear regression analysis, with BMD as the dependent variable and BMI, age, and adiponectin as independent variables, was also done. The analysis suggests that the lumbar BMD maintain an independent relationship with adiponectin (Table 3). By contrast, there was no significant correlation between adiponectin and BMD in another subgroup of men having BMI $\leq 27$.

**Discussion**

The direct association existing between body weight and the reduction of fractures has been shown in various studies (2, 22–24). Although there are several factors, such as mechanical loading forces, aromatization of testosterone in adipose tissue, and insulin concentrations, which may contribute to the relationship between body weight and BMD recently it has been shown that some adipocytokines secreted by adipose tissue play a role in bone metabolism (6–8). Adiponectin is one of the hormones that support the link between adipose and bone tissue (12). It has been observed that the serum concentrations of this hormone correlate negatively with BMD in the female population (9, 15, 17, 18); however, there are only limited number of studies conducted to determine this relationship in men (25, 26).

The present study showed an inverse association between the adiponectin concentrations and the bone density in men older than 60 years. These findings agree with the study by Peng et al. which was conducted on a population of a very wide age range (20–80 years) and, therefore, with significant BMD variations (25). On the contrary, in another study on males (26), no association was found between adiponectin and BMD; however, the small sample size, lack of adjustment in

---

**Table 2** Correlations between the adiponectin levels and bone mineral density (BMD).

<table>
<thead>
<tr>
<th></th>
<th>Adiponectin</th>
<th>Unadjusted</th>
<th>Adjusted for age</th>
<th>Adjusted for BMI</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spine (L1–L4)</td>
<td>$-0.209^*$</td>
<td>$-0.155^*$</td>
<td>$-0.126$</td>
<td></td>
</tr>
<tr>
<td>Femoral</td>
<td>$-0.237^t$</td>
<td>$-0.195^*$</td>
<td>$-0.093$</td>
<td></td>
</tr>
</tbody>
</table>

$^*P<0.05$, $^tP<0.001$.

---

**Table 3** Regression coefficient $\beta$ for independent predictors of bone mineral density (BMD) in total participants, participants with body mass index (BMI) $>27$, and participants with BMI $\leq 27$.

<table>
<thead>
<tr>
<th></th>
<th>Total participants ($n=92$)</th>
<th>Participants BMI $&gt;27$ ($n=50$)</th>
<th>Participants BMI $\leq 27$ ($n=42$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adiponectin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>$0.198$</td>
<td>$0.268$</td>
<td>$0.307$</td>
</tr>
<tr>
<td>Age</td>
<td>$0.288$</td>
<td>$0.074$</td>
<td>$0.072$</td>
</tr>
<tr>
<td>Adiponectin</td>
<td>$-0.074$</td>
<td>$0.464$</td>
<td>$0.456$</td>
</tr>
</tbody>
</table>

$\beta$ coefficient: standard regression coefficient. $P$ values $<0.05$ are shown in bold.
some confounding variables (alcoholism and tobacco addiction), and the participants’ wide age range could have affected the results of this study (27–29). By contrast, for the present study it was agreed to choose men older than 60 years of age, since this is the stage of life in which demineralization problems become apparent.

Although the results of some studies have been contradictory, the possible relationship between adiponectin and BMD is supported by the evidence, such as the identification of adiponectin receptors in both osteoblasts and osteoclasts (30), and the proof that adiponectin increases osteoclastogenesis indirectly by stimulating RANKL and by inhibiting the production of osteoprotegerin in human osteoblasts (31, 32).

The results of the present study demonstrated a strong relationship between the adiponectin levels and BMD in participants who presented greater BMI. Moreover, a multiple regression analysis indicated that adiponectin is an independent predictor of BMD in this subgroup of men. Conversely, these associations were not observed in patients with BMI ≤ 27. To this respect, other factors like altered levels of estrogens, insulin, and other adipokines in obesity, modifying the relationship between adiponectin and bone, could be explain the differences (17, 33).

This study has some limitations. Since it was not designed for stratified analysis, it is required that the studies directed towards evaluating the possible differences between participants with normal weight and overweight should be conducted. Another consideration of this study is that BMI was used only to measure body fat, although there are other precise methods like DXA scan. The BMI does not quantify total body adiposity, but is correlated with body fatness and is a method accepted to measure obesity (34, 35). Furthermore, even though this study was cross-sectional and therefore inferences of causality cannot be established, the results may suggest that adiponectin might play a role in the bone balance, particularly in elderly men with overweight. On the other hand, it can be pointed out that the influence of potential confounders was reduced by limiting the age, heavy physical activity, tobacco addiction, and alcoholism in the inclusion criteria of the present study.

In conclusion, this study demonstrated that men older than 60 years of age exhibit an inverse relationship between the adiponectin levels and BMD, particularly when BMI is above normal limits. However, no definitive conclusions can be obtained; the study data support that adiponectin is involved in the interrelationship between adipose tissue and bone.

Declaration of interest

The authors declare that there is no conflict of interest that would prejudice the impartiality of this paper.

Funding

This work was supported in part by a grant FOFOI 2006/1A1/056 from the Mexican Institute of Social Security (IMSS).

Acknowledgements

We thank Elizabeth Garcia and Sara Vega for their technical assistance.

References


Received 10 November 2008
Accepted 13 November 2008